Loading clinical trials...
Loading clinical trials...
The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an in...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Shionogi
Collaborators
NCT07230834 · Geographic Atrophy (GA)
NCT05748028 · Parkinson Disease, Multiple System Atrophy
NCT05866419 · Spinal Muscular Atrophy, Spine Deformity, and more
NCT05204017 · Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, and more
NCT06839469 · Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions